Obtenga las últimas noticias sobre las acciones de Reviva Pharmaceuticals con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de RVPH

Últimas noticias sobre

REVIVA PHARMACEUTICALS HOLDI

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAP

AGMH

AIIO

ASST

ATCH

ATMV

CEVA

FTHM

KAPA

LASE

MGIH

RNAZ

RVPH

SCHL

SOWG

VTEX

XXII

Las acciones de FedEx (FDX) suben un 5%; Aquí están 20 acciones que se mueven en el pre-market de EE.UU.

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. - Warrants

Press Releases

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Health Care

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

IPOs

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Earnings

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference

Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Assertio Holdings

Biote

CalciMedica

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Grace Therapeutics

Hyperion DeFi

IGC Pharma

ImageneBio

Intercure

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

NRX Pharmaceuticals

Nasus Pharma

Nutriband

PolyPid

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SCYNEXIS

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Talphera

Tvardi Therapeutics

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Chardan Capital

D. Boral Capital

Benchmark

Roth Capital

Maxim Group

Screenshot 2025-09-23 at 9.53.22 PM

Biotech

Interview

Reviva Pharmaceuticals CEO Tells Benzinga About The Trouble With Today&#39;s Schizophrenia Drugs – And How The Company Is Fixing That

Screenshot 2025-08-27 at 5.42.58 PM

General

Reviva Pharmaceuticals Makes Progress With Late-Stage Novel Multimodal Neuromodulator Drug For Schizophrenia, Other Brain Diseases

Comments

Reviva Pharmaceuticals Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL